SOURCES SOUGHT
65 -- Production of blocking Rabbit Monoclonal Antibody against human CD97.
- Notice Date
- 7/13/2016
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC62562-61
- Archive Date
- 8/11/2016
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: July 27, 2016 by 11:00 AM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified Small Business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 325413 with a size standard of is 500 employees. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E1644, Bethesda, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Cancer Center Research (CCR), The Laboratory of Genitourinary Cancer Pathogenesis (LGCP) plans to procure on a sole source basis for a custom rabbit monoclonal blocking antibody directed against human CD97 manufactured by Abcam Burlingame, 863 Mitten Road, Suite 103-104, Burlingame, CA 94010-1303. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 325414 and the business size standard is 1250. Period of performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Purpose of this acquisition for The National Cancer Institute, Laboratory of Genitourinary Cancer Pathogenesis (LGCP) to procure a custom rabbit monoclonal blocking antibody directed against human CD97. This antibody will be generated through fusion of spleen cells of immunized rabbits with Rabbit Plasmacytoma cells. Antibodies from rabbits are generally of higher affinity than those from mice. Results obtained from the contractor and other researchers indicate that the binding affinity of rabbit monoclonal antibodies is on average 100 times higher, offering better sensitivity and specificity in biological assays. Rabbit monoclonal antibodies recognize many antigens that are not immunogenic in mice, including small molecule haptens, some cell surface epitopes, modified sites (e.g., phosphorylation, acetylation, methylation, glycosylation, etc.) and most rodent proteins. The rabbit system offers 40 times as many lymphocytes compared to mouse and the 240E cell line used for fusion is much more robust than any of the mouse cell lines used for fusion. Because of the large size of the rabbit spleen, more fusion experiments can be performed, making hybridoma generation at industrial scale a feasible task. The contractor shall generate up to 9 hybridoma subclones from as many as 3 parent hybridoma cell lines chosen by NCI/LGCP as a result of screening. The production required to blocking Rabbit Monoclonal Antibody possesses the following salient characteristics: Phase I: Rabbit Polyclonal Antibody Service - Immunization of two (2) rabbits using standard immunization of five (5) injections and collection of one (1) pre-bleed and two (2) test bleeds per rabbit. - Monitor antiserum titer using standard ELISA. - Counter-screen with Fc fusion protein. - Discuss titer results with NCI to select rabbit for splenectomy. - Final IV and splenectomy (Final IV must be scheduled within 4-8 weeks of last regular injection boost). Phase IIa: Rabbit Monoclonal Antibody Service - Isolate all the lymphocytes from one rabbit spleen. - Store all remaining lymphocytes in liquid nitrogen for up to three (3) months after the termination of the project. Phase IIb: Rabbit Monoclonal Antibody Service - Perform hybridoma fusion of 80 x 96-well plates. - Perform standard ELISA screening of 80 x 96-well plates. - Expand all positive hybridomas to 24-well plates and perform confirming standard ELISA. - Counter-screen with Fc Fusion Protein. - Transfer and deliver all standard ELISA positive multi-clone supernatants (1 ml each) for a two week screening by NCI. Phase IIIa: Rabbit Monoclonal Antibody Service - Subclone up to 3 multclone hybridomas chosen by NCI. - Perform standard ELISA screening of supernatants. - For each hybridoma chosen, deliver supernatants (1 ml each) from subclones for a two week screening by NCI. - Freezing and storage of backup (3) multiclone hybridomas. Phase IIIb: Rabbit Monoclonal Antibody Service - Expand up to nine (9) final hybridoma subclones from each parental clone as frozen cells. - Store subclones for three (3) months following project completion. Phase IIIc: Rabbit Monoclonal Antibody Service - Culture one (1) hybridoma subclone (1L). - Perform two (2) hybridoma supernatant harvest collections. - Perform standard ELISA screening and spectroscopic concentration determination of supernatant. - Purify the hybridoma supernatant using a Protein A column. - Analyze the purify sample via gel electrophoresis, spectroscopic concentration determination, and ELISA. How to Submit a Response: 1. Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12-point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2. Due Date: Capability statements are due no later than 11:00 AM. EST on July 27, 2016. 3. Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Kathy Elliott Contract Specialist at Elliottk@mail.nih.gov or mailed to the address located under Point of Contact. All questions must be in writing and submitted via email. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through www.sam.gov. No collect calls will be accepted. Please reference number N02RC62562-61on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Kathy Elliott Elliottk@mail.nih.gov Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC62562-61/listing.html)
- Place of Performance
- Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04180347-W 20160715/160713234207-44da543cef87506d0e0134b483fa3e33 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |